Tema ETFs LLC Purchases 3,956 Shares of AbbVie Inc. $ABBV

Tema ETFs LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.8% during the second quarter, Holdings Channel reports. The institutional investor owned 61,759 shares of the company’s stock after acquiring an additional 3,956 shares during the quarter. Tema ETFs LLC’s holdings in AbbVie were worth $15,541,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in ABBV. Norges Bank bought a new stake in AbbVie in the fourth quarter valued at about $5,865,055,000. Wellington Management Group LLP raised its position in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Capital World Investors lifted its stake in AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. Cardano Risk Management B.V. boosted its holdings in AbbVie by 914.6% during the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Royal Bank Of Canada lifted their price objective on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Finally, HSBC restated a “buy” rating and issued a $300.00 target price on shares of AbbVie in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $274.33.

AbbVie Price Performance

NYSE ABBV opened at $249.73 on Wednesday. The stock’s 50 day simple moving average is $243.35 and its 200 day simple moving average is $225.51. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The firm has a market cap of $441.22 billion, a PE ratio of 70.54, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio is 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Apogee Therapeutics shareholders approved AbbVie’s approximately $10.9 billion cash acquisition, helping remove a key closing hurdle. The deal is expected to expand AbbVie’s immunology pipeline with zumilokibart, an atopic dermatitis candidate advancing toward Phase 3 trials, while Apogee’s leadership transition is expected to support integration. Apogee Shareholders Approve AbbVie Acquisition and Leadership Transition
• Positive Sentiment: AbbVie’s Skyrizi and Rinvoq continued to drive strong quarterly growth through market-share gains and additional indications, reinforcing the company’s strategy for replacing revenue eventually pressured by Humira biosimilars. How Much Did Immunology Drugs Contribute to AbbVie’s Q2 Performance?
• Positive Sentiment: The FDA accepted a supplemental application to review Botox Cosmetic for treating masseter muscle prominence. Approval would create a potential fifth use for the brand and modestly broaden AbbVie’s aesthetics growth opportunity. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
• Neutral Sentiment: BNP Paribas Exane raised its ABBV price target from $218 to $247 but maintained a Neutral rating, suggesting limited upside after the recent rally. BNP Paribas Exane AbbVie Price Target Update
• Neutral Sentiment: Investor commentary remains constructive on AbbVie’s dividend and valuation, with some analysts describing the stock as an attractive income-oriented healthcare investment after its solid second-quarter performance. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
• Negative Sentiment: AbbVie is reportedly taking on roughly $8 billion of debt to help fund the Apogee transaction. While the acquisition could strengthen long-term growth, added leverage may increase interest costs and concern dividend investors if expected pipeline returns take longer to materialize. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal
• Negative Sentiment: Erste Group Bank trimmed its FY2027 EPS forecast from $16.40 to $16.24, although it retained a Buy rating. The revision is a modest headwind amid ABBV’s elevated price-to-earnings multiple.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.